1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6732DA6E3036A397E85256E3C00823AA0
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/white-paper-developing-global-trademarks-benchmarking-strategy-process?opendocument
18
19opendocument
2052.23.234.7
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25RAS




Products & Services

White Paper: Developing Global Trademarks: Benchmarking Strategy & Process

Whitepaper Image

ID: BEB-04


Pages/Slides: 6


Published: Pre-2014


Delivery Format: PDF


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Download White Paper

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS

This study excerpt is a sample from a 40-slide study that identifies the strategies and processes used by leading companies to develop global trademarks. The entire study is available for resale in the best Practice Database.

Best Practices, LLC surveyed 13 pharmaceutical or biotechnology companies to compare strategies and processes to developing global trademarks. Executives with seven of these companies were also interviewed to discuss their approaches and lessons learned.

This research was conducted on behalf of the Business Excellence Board -- a membership-based research and advisory service.

Industries Profiled:
Medical Device; Pharmaceutical; Biotech; Health Care


Companies Profiled:
3M Pharmaceuticals; Sanofi-aventis; AstraZeneca; Eli Lilly; Genzyme; Johnson & Johnson; Merck; Navigant; Pfizer; Schering-Plough